Liquidia Corporation Common Stock (LQDA) trades on Nasdaq and is classified in the Healthcare sector. Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. This page tracks LQDA using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.
Previous close
$26.81
Volume
21,104,222
52-week range
$21.94 – $93.61
Market cap
$2.40B
Source: Polygon (snapshot) · Verified Oct 14, 2026, 6:12 PM EDT
1D
+25.74%
1W
+27.21%
1M
-48.03%
1Y
+49.06%
Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.
Revenue (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue growth (YoY)
Reported Q2'26 · Polygon (company financials)
EPS (TTM, diluted)
Reported Q2'26 · Polygon (company financials)
EPS growth (YoY)
Reported Q2'26 · Polygon (company financials)
Gross margin
Reported Q2'26 · Polygon (company financials)
Operating margin
Reported Q2'26 · Polygon (company financials)
Net margin
Reported Q2'26 · Polygon (company financials)
Operating cash flow (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue 2-year CAGR
Reported Q2'26 · Polygon (company financials)
Source: Polygon financials + Finnhub earnings · Latest reported Q2'26 · Verified Aug 11, 2026, 8:00 PM EDT
P/E (trailing)
Reported Q2'26 · Ticker-Terminal (last verified price ÷ TTM diluted EPS)
P/E (forward, est.)
Market cap
Polygon / Finnhub reference
Dividend yield
Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.
Next earnings date
Nov 9, 2026
Source: Finnhub earnings calendar
Latest reported quarter
Q2'26
Revenue $171.7M · Diluted EPS 0.74
| Period | EPS actual | Estimate | Surprise |
|---|---|---|---|
| 2026-06-30 | 0.74 | 0.76 | -2.3% |
| 2026-03-31 | 0.52 | 0.42 | +24.3% |
| 2025-12-31 | 0.17 | 0.18 | -7.6% |
| 2025-09-30 | -0.04 | -0.41 | +90.2% |
Bear $43.92 · Base $54.90 · Bull $65.88 — Significantly Undervalued versus the last verified price.
Sustained growth and margin strength support roughly $65.88.
Current reported earnings power maps to roughly $54.90 (significantly undervalued versus the last verified price).
Multiple compression or slowing growth maps to roughly $43.92.
Calculated from verified reported financials and the last verified price (data verified Oct 14, 2026, 6:12 PM EDT). Analytical model output, not a price target or investment advice.
Rating
Buy
Average target
Unavailable
Range
Unavailable
Analysts
15
Source: finnhub
Zacks Investment Research · Oct 14, 2026
Yahoo Finance · Oct 13, 2026
Benzinga · Oct 14, 2026
Benzinga · Oct 14, 2026
Yahoo Finance · Oct 13, 2026
Benzinga · Oct 14, 2026
Market and financial inputs are verified and current.
Company profile and business overview · Reported financial statements · Earnings history · Ticker-Terminal analysis
This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Liquidia Corporation Common Stock trades under the ticker LQDA on Nasdaq.
LQDA was last verified at $33.71 (25.74% on the day). After hours, last verified Oct 14, 2026, 6:12 PM EDT. Market data may be delayed and is shown with its own timestamp.
Based on the latest reported financials, LQDA revenue changed 1842.7% year over year (filed Aug 11, 2026).
The next confirmed LQDA earnings date is Nov 9, 2026, per Finnhub earnings calendar. Dates can be revised by the company.
For Q2'26, LQDA reported revenue of $171.7M and diluted EPS of 0.74.
Ticker-Terminal scores LQDA at 100/100 (A+) from verified growth, profitability, financial strength and valuation inputs. It is an analytical model based on available verified data, not a guarantee of future performance.
Create a free Ticker-Terminal account to run a full AI research report on LQDA — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.
Free guide series
Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.
Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from LQDA's most recently reported statements and are not restated by Ticker-Terminal.
Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.
See our risk disclosure. Page data assembled Oct 14, 2026, 6:28 PM EDT.